吉利德科学 2024年度报告

2025 OUR CORE VALUES OUR VISION To create a healthierworld for all people IntegrityAccountabilityTeamworkInclusionExcellence OUR MISSIONTo discover, develop and deliver innovativetherapeutics for people withlife-threatening diseases OUR CORPORATE STRATEGY STRATEGIC PRIORITIES (REFRESHED IN 2023) LONG-TERM AMBITIONS ⊲Maximize Near-Term Revenue Growth⊲Maximize Impact of Long-acting HIV Therapies⊲Expand and Deliver on Oncology Programs⊲Champion an Environment of Inclusion andEmployee Growth⊲Remove Barriers to Speed in Execution Bring 10+ Transformative Therapiesto Patients by 2030 Be a Biotech Employer and Partnerof Choice Deliver Shareholder Value in aSustainable, Responsible Manner Letter from Our Chairmanand Chief Executive Officer Dear Stockholders, Our portfolio of therapies for inflammatory diseases is alsopromising and growing. In 2024, we launched Livdelzi®, atransformative treatment for primary biliary cholangitis (PBC), arare liver disease that primarily affects women. Initial demandin the U.S. exceeded our expectations, and we look forwardto reaching more patients this year. On the pipeline side, werecently entered into a strategic partnership with LEO Pharmato accelerate the development and commercialization of anoral STAT6 program for the potential treatment of patients withinflammatory diseases. Thank you for investing in Gilead at one of the most excitingmoments in our company’s history. Following the investmentswe havemade in recent years – and the results they aredriving –we are in an exceptionally strong position to deliveron our mission in 2025 and beyond. As you know, our transformation has focused on drivinginnovation in three therapeutic areas: virology, oncology andinflammation.I ampleased to share that all three are set to drivelong-term growth for our business and deliver impact for patientsand communities worldwide. Importantly, all these advancements across our portfolio haveoccurred alongside major improvements in our operationalefficiency. We are doubling down on the business areas thatwill drive our growth in both the near- and long-term, whilesignificantly reducing costs in other areas. We have strongconviction in our ability to simultaneously drive revenue growthand cost savings, which we believe will continue to drivecompelling value for our stockholders. One of our most exciting breakthroughs on the horizon isthe world’s first twice-yearly injection for HIV prevention,lenacapavir. Named the 2024 Breakthrough of the Year byScience Magazine, lenacapavir has shown unprecedentedefficacy in clinical trials and is poised to transform the globalfight against HIV if approved by the FDA this summer. Inaddition to lenacapavir, our once-daily HIV prevention tabletBiktarvy® continues to command the majority of market share inthe United States. With up to nine upcoming HIV launches andno patent expirations until 2033, we are positioned to extendour global leadership in HIV through the 2030s and beyond. Finally, I would like to acknowledge the invaluable contributionsof our highly experienced and dedicated Board of Directors.Their collective expertise, strategicvision andcommitment toGilead’s long-term success are instrumental in driving our growthand opportunities for value creation. In 2024, our Board evolvedfurther as we welcomed Ted Love,M.D., as our newestdirector,and appointed Anthony Welters as Lead Independent Director. In oncology, our portfolio is broad and innovative, with29clinical and 28 preclinical programs. We anticipate the launchof anito-cel, a potential best-in-class cell therapy, in multiplemyeloma in 2026. Kite’s exceptional manufacturing capabilitiesand industry-leading turnaround time put us in a strong positionto address the significant unmet need for patients with this typeof blood cancer. In addition, Trodelvy remains the only approvedTrop-2 antibody drug conjugate to demonstrate overall survivalbenefit in two types of breast cancer, and we have six ongoingPhase 3 trials with the medication. All told, our oncologytherapies have already reached more than 80,000 peoplethrough 2024, and we believe this is only the beginning. Aswe look to the promising future ahead, and on behalf ofthe entire Board of Directors and everyone at Gilead, thankyou for your support as we work to create a healthier world forallpeople. Sincerely, Daniel O’DayChairman and Chief Executive Officer Letter from Our LeadIndependent Director Dear Stockholders, In an effort tohelpour medicines reach the people who needthem most, Gilead is committed to breaking down barriers to carein communities worldwide.To that end, we took animportantstep forwardin 2024by establishinga strategy to provide accessto lenacapavir for prevention, when approved, through voluntarylicensing agreements and global partnerships to more than 120primarily low- and lower-middle income countries. In addition,we extendedourRADIAN® partnership with the Elton John AIDSFoundation with a $25 million investm